Currently, positron emission tomography (PET) imaging and cerebrospinal fluid (CSF) biomarkers involve assessing β-amyloid (Aβ) and phosphorylated tau peptides to monitor and diagnose AD are used [3]. This evidence concerns the gene MAPT and Alzheimer disease.